Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Benzinga · 04/11/2025 10:50
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.